Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117569 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117382 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117383 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117541 | 0.94 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL22117539 | 0.94 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL28652782 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL28652783 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29461968 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30592738 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29461983 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3898652-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | NPY4R 2540/4885NPY1R 2382/4885NPY5R 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.